NASH Drug Pipeline: GLP-1s Lead, But Liver-Specific Targets Emerge
Review of NASH therapeutics shows GLP-1 agonists dominating near-term approvals, while novel liver-specific mechanisms offer differentiated approaches.
Published May 22, 2026·4 min read·Evidence: Peer Reviewed
What They Found
This review surveys the current therapeutic landscape for NASH (now termed MASH - metabolic dysfunction-associated steatohepatitis). The authors map both FDA-approved treatments and the clinical pipeline, highlighting how GLP-1 receptor agonists have emerged as frontline therapy while novel liver-specific targets advance through trials.
Why It Matters
NASH affects 3-5% of the global population and represents the fastest-growing indication for liver transplantation. The therapeutic approach has shifted dramatically over the past 3 years. Semaglutide and tirzepatide now serve as first-line treatments, not primarily for their liver effects, but because they address the upstream metabolic drivers - insulin resistance, weight gain, and systemic inflammation.
The review likely details emerging mechanisms beyond incretin signaling: FXR agonists targeting bile acid metabolism, PPAR agonists addressing lipid oxidation, and anti-fibrotic agents like cenicriviroc. These liver-specific approaches matter because GLP-1s, while effective for metabolic parameters, show modest direct hepatic benefits. Patients often need 10-15% weight loss to see meaningful liver histology improvement with incretin therapy alone.
What's particularly relevant is the combination therapy trend. NASH is a multi-hit disease - you need to address insulin resistance, hepatic lipotoxicity, inflammation, and fibrosis simultaneously. Single-target approaches consistently underperform in phase 3 trials.
What I'd Watch For
This appears to be a narrative review, not primary research, so the value depends entirely on how comprehensively they covered the pipeline and whether they included recent trial failures. Many NASH drugs that looked promising in phase 2 have crashed in larger studies when histological endpoints were required.
The real question is whether they addressed the diagnostic challenge. NASH diagnosis still requires liver biopsy in most cases, making patient selection for clinical trials problematic and real-world treatment initiation difficult.
Bottom Line
GLP-1 agonists are currently your best NASH intervention, but primarily through metabolic improvement, not direct liver effects. The liver-specific pipeline remains promising but unproven at scale. Until we have better non-invasive diagnostics, NASH treatment will remain reactive rather than preventive.